Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib Maintenance in Platinum-Sensitive Ovarian Cancer
NCT01972516Phase 2
Key facts
- Status
- Terminated
- Start
- Nov 2013
- Primary completion
- Jul 2015
- Countries
- 1
- Sponsor
- Dana-Farber Cancer Institute
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Drugs
- tivozanib
- Conditions
- ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
01
Overview
Phase 2, randomised, open-label trial of tivozanib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Progression-Free Survival at 2 Years. Started Nov 2013; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
Tivozanib
Tivozanib 1.5 mg/day orally, 3 weeks on / 1 week off.
Standard Care
Standard clinical observation.
03
Endpoints
Primary
Progression-Free Survival
Secondary
Progression-Free Survival
Overall Survival
Toxicity Rate Comparison
Quality of Life Evaluation
Beyond the preview
Go deeper on NCT01972516.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01972516.